Source: Reuters
“The U.S. Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, branded as Inlexzo, was approved for patients with a type of high-risk non-muscle invasive bladder cancer who did not respond to treatment with Bacillus Calmette-Guerin therapy, the current standard-of-care, and are ineligible for, or refuse to undergo bladder removal surgery. … The approval was based on data from a mid-stage study, in which more than 82% of the patients who received Inlexzo showed no signs of cancer, and over half of them remained cancer-free for at least a year.” (09/10/25)